肾康丸对早期糖尿病肾病大鼠足细胞损伤的保护作用  

Protective effects of Shenkangwan against podocyte injury in rats with early diabetic nephropathy

作　　者：龙海波[1] 张辉[1] 钟娟[1] 朱艳[1] 何井华[1] 魏连波[1] 

机构地区：[1]南方医科大学珠江医院中西医结合肾病中心,广东广州510282

出　　处：《南方医科大学学报》2008年第7期1268-1272,共5页Journal of Southern Medical University

基　　金：南方医科大学珠江医院院长基金(200403)

摘　　要：目的观察肾康丸对糖尿病肾病(DN)大鼠肾小球足细胞形态及desmin、podocin表达的影响,探讨肾康丸对DN的肾保护作用机制。方法应用链脲佐菌素建立大鼠DN模型,将DN模型大鼠随机分为4组:DN模型对照组、肾康丸组、厄贝沙坦组、肾康丸和厄贝沙坦合用组;另设正常对照组。各组分别干预8周后,观察24h尿蛋白定量变化,利用光镜、电镜观察肾脏病理改变,应用免疫组化技术观察足细胞desmin、podocin表达变化。结果应用肾康丸、厄贝沙坦干预后,DN大鼠24h尿蛋白定量明显减少,肾脏病理改变显著减轻,足细胞desmin表达明显减少、podocin表达明显增加。结论通过上调足细胞podocin的表达,使podocin的合成增加,从而减轻足细胞的损伤、维护足细胞结构和功能的完整性,可能是肾康丸对DN的肾保护作用机制之一。Objective To investigate the morphological changes and expressions of desmin and podocin in podocytes of rats with diabetic nephropathy （DN） rats and renal protection mechanism of Shenkangwan. Methods DN model was established in rats by a single injection of streptozotocin. The rats were then randomly divided into model group, Shenkangwan treatment group, irbesartan treatment group, and Shenkangwan plus irbesartan treatment group, with normal rats as the control group. All the rats received daily gavage for 8 weeks. The urinary protein quantity in 24 h were detected, and the morphological changes of the kidneys were observed with optic and transmission electron microscopes. The expressions of desmin and podocin in the podocytes were detected by immunohistochemistry. Results Shenkangwan and irbesartan reduced the urinary protein quantity in 24 h and alleviated the renal damage in DN rats, and the expression of desminwas significantly attenuated while podocin expression increased in the podocytes. Conclusions Shenkangwan can provide renal protection against DN in rats and alleviate the structural and functional damages ofpodocytes possibly by reducing desmin expression and increasing podocin expression in the podocytes.

关 键 词：糖尿病肾病 足细胞 肾康丸 厄贝沙坦 DESMIN PODOCIN 

分 类 号：R285.5[医药卫生—中药学]